Sterling Pharma to acquire CiVentiChem in the US9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.
UK-based CDMO, Sterling Pharma Solutions, has announced its acquisition of CiVentiChem’s US facility located in Cary, North Carolina, US.
The new facility, located close to the Research Triangle Park, will allow Sterling to offer a local presence to its US clients and enhance its chemistry development capabilities to support pre-clinical and early phase clinical supply.
The acquisition follows Sterling’s record growth, with the company more than doubling its sales since its formation in 2016 following a management buy-out (MBO). With the support of its new investor, GHO Capital, the acquisition advances Sterling’s strategy to build a global chemistry services business.
Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said: “We’re delighted to announce our acquisition of CiVentiChem in the US. We’ve been keen to expand our presence in the US market and the site’s capabilities complement our current service offering.
“The North American market now makes up 70% of our customer portfolio which was one of the major reasons behind the decision to look for a facility in the US. This has been primarily driven by the market’s emerging pharma sector and customer demand for our specialist capabilities in complex and challenging chemistry.”
The acquisition of CiVentiChem US is the latest step in Sterling Pharma Solutions’ ongoing growth strategy to allow it to continue providing high service levels to its global customer base.
The purchase of the new facility follows the completion of a majority acquisition of Sterling Pharma Solutions by the specialist European healthcare investor, GHO Capital earlier this year.
Sterling Pharma Solutions is the UK’s largest provider of small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. With over 50 years’ experience, the team can manage the most complex API and API intermediate challenges and its facilities have the scale to go from proof-of-concept to commercial manufacture.
CiVentiChem is a leading provider of solutions for complex chemistry problems across the pharmaceutical, biotech and life sciences industry. Founded by Dr. Bhaskar Venepalli and Dr. Srinivas Chittineni, CiVentiChem’s US facility houses development laboratories and kilo scale cGMP suites.
“We have developed excellent relationships with many clients and this acquisition will make Sterling a global player in CDMO business” said Bhaskar Venepalli, CiVentiChem President and CEO. CiVentiChem will continue to operate out of its own facility in India as a separate entity to Sterling.
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk
11 Jun 2019
No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.Read more
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma
6 Jun 2019
Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.Read more
Lilly gets its hands on non-opioid pain asset
4 Jun 2019
Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.Read more
Updated clinical trial simulation software saves time and money
3 Jun 2019
One customer saves $25m and 3 years' development time in their clinical development strategy.Read more
Merck bolsters oncology pipeline with acquisition
22 May 2019
Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.Read more
Follicum files patent application for new topical formulation for hair loss
30 Apr 2019
Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation